Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $41.83

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have received an average recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $41.8333.

Several equities analysts have weighed in on the company. Canaccord Genuity Group lifted their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Needham & Company LLC boosted their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Wall Street Zen downgraded Stoke Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Finally, Wedbush boosted their price objective on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th.

Stoke Therapeutics Price Performance

NASDAQ STOK opened at $31.00 on Monday. The company has a market cap of $1.93 billion, a P/E ratio of -11.03 and a beta of 1.17. The stock has a 50-day moving average of $31.93 and a two-hundred day moving average of $32.36. Stoke Therapeutics has a 1-year low of $11.17 and a 1-year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.01. The company had revenue of $6.23 million during the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. On average, analysts anticipate that Stoke Therapeutics will post -3.22 EPS for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 1,795 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the transaction, the insider directly owned 34,826 shares of the company’s stock, valued at approximately $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total value of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares of the company’s stock, valued at approximately $541,675.70. This represents a 7.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in STOK. Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics during the fourth quarter worth approximately $26,000. KBC Group NV purchased a new stake in Stoke Therapeutics during the first quarter worth approximately $36,000. Harbour Investments Inc. lifted its stake in Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the last quarter. Generali Investments Management Co LLC purchased a new stake in Stoke Therapeutics during the third quarter worth approximately $41,000. Finally, BNP Paribas Financial Markets lifted its stake in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.